Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

    ... Patient must have received crenolanib on this protocol prior to HSCT to continue on to maintenance. Patient must be ... (HSCT). Response to previous treatment on this protocol: at least resistant disease with clinical benefit or better response. ...

    Clinical Trial last updated 06/06/2016 - 10:04am.

  2. AAMDSIF Emily Kass Research Fund

    ... marrow failure disease, MDS.  As there wasn’t any protocol for treating a pediatric MDS patient, numerous specialists around ...

    Research Fund last updated 06/08/2017 - 3:35pm.

  3. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    Journal Title:  Ann Hematol Primary Author:  Mittelman M Author(s):  Mittelma...

    Research Article last updated 09/13/2016 - 2:47pm.

  4. Sicheng Wen, MD, PhD

    ... reverse chronic aplastic anemia in our current protocol , we need further optimize the dose of MSC-EVs. We further ...

    Grant Recipient last updated 01/05/2018 - 1:09pm.

  5. Transplants With Unlicensed Preserved Cord Blood

    ... if the transplant will occur under an IND research protocol . These units are in current and future inventory at domestic and ... Indications. This study is an access and distribution protocol conducted by the National Marrow Donor Program (NMDP) for unlicensed ...

    Clinical Trial last updated 04/27/2016 - 3:20pm.

  6. An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia

    ... of adequate method of contraception are shown in the protocol section 4.1.10 Women are considered post-menopausal and not of ... Patients unwilling or unable to comply with the protocol . Pregnant or breastfeeding Acute promyelocytic leukemia ...

    Clinical Trial last updated 06/06/2016 - 1:26pm.

  7. Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies

    ... C, but have a negative viral load, are eligible. f. The protocol chairman will determine the eligibility of patients related to ... antimicrobial agents after seven days of therapy. The Protocol PI is the final arbiter of eligibility. Pleural/pericardial ...

    Clinical Trial last updated 06/06/2016 - 1:18pm.

  8. A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects with PNH

    ... pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study Males must agree to use protocol defined methods of contraception and agree to refrain from donating ...

    Clinical Trial last updated 07/19/2016 - 12:46pm.

  9. Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

    ... allogeneic peripheral blood stem cell (PBSC) transplant protocol (03-H-0170) for patients with severe sickle cell disease (SCD) and ... (and reduce the transplant failure rate) in this new protocol, we will continue our nonmyeloablative approach in the patients with ...

    Clinical Trial last updated 04/28/2016 - 9:09am.

  10. A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH

    ... pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study ... female partners of child bearing potential must agree to use protocol defined methods of contraception (see below) and agree to refrain from ...

    Clinical Trial last updated 08/24/2016 - 11:15am.